Supplemental Materials Fig. S1. Efficacy and tolerability of MK-0893 in patients with type 2 diabetes (T2DM) (). Details of the study design was described previously by Engel (). The patient numbers et al included in this trial are: placebo (n = 57), MK-0893 20 mg QD (n =57), MK-0893 40 mg QD (n = 57), MK-0893 60 mg QD (n = 58), MK-0893 80 mg QD (n = 56), and metformin 1000 mg BID (n = 57). Abbreviations: BL FPG, baseline fasting plasma glucose; change of FPG FPG, after 12-wk treatment from baseline; BL A1C, %, baseline plasma level of HbA1C %; A1C,  %, change of A1C after 12-wk treatment from baseline; BL LDL-C, baseline plasma level of LDL-C; % LDL-C, percent change of plasma LDL-C after 12-wk treatment from baseline;  MF, metformin. Fig. S2. Comparison of effects of MK-0893 on glucagon-induced glucose excursion and plasma phytosterols in WT and mice. Male WT and mice at 12-16 wks of age were hGCGR hGCGR treated with vehicle and MK-0893 (3 and 10 mpk, QD) for 5 days (n = 8). (A and B) glucose excursion after single dose on day 1 in WT and mice. (C) Plasma hGCGR levels of phytosterols in WT and mice on day 5. hGCGR
Supplemental Materials Fig. S1. Efficacy and tolerability of MK-0893 in patients with type 2 diabetes (T2DM) (). Details of the study design was described previously by Engel et al (). The patient numbers included in this trial are: placebo (n = 57), MK-0893 20 mg QD (n =57), MK-0893 40 mg QD (n = 57), MK-0893 60 mg QD (n = 58), MK-0893 80 mg QD (n = 56), and metformin 1000 mg BID (n = 57). Abbreviations: BL FPG, baseline fasting plasma glucose; FPG, change of FPG after 12-wk treatment from baseline; BL A1C, %, baseline plasma level of HbA1C %;  A1C, %, change of A1C after 12-wk treatment from baseline; BL LDL-C, baseline plasma level of LDL-C; %  LDL-C, percent change of plasma LDL-C after 12-wk treatment from baseline; MF, metformin. Fig. S2. Comparison of effects of MK-0893 on glucagon-induced glucose excursion and plasma phytosterols in WT and hGCGR mice. Male WT and hGCGR mice at 12-16 wks of age were treated with vehicle and MK-0893 (3 and 10 mpk, QD) for 5 days (n = 8). (A and B) glucose excursion after single dose on day 1 in WT and hGCGR mice. (C) Plasma levels of phytosterols in WT and hGCGR mice on day 5.
jlr.M060897-1.docx